{
    "code": "02023396",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02023396",
    "time": "2023-08-31 22:56:38",
    "許可證字號": "衛署藥輸字第023396號",
    "註銷狀態": "已註銷",
    "註銷日期": "112\/06\/05",
    "註銷理由": "許可證已逾有效期",
    "製造許可登錄編號": "",
    "有效日期": "111\/03\/11",
    "發證\/登錄日期": "91\/03\/11",
    "許可證\/登錄種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA00202339606",
    "中文品名": "安莎德斯注射液",
    "英文品名": "Anzatax  Injection Concentrate",
    "適應症": "晚期卵巢癌、腋下淋巴轉移之乳癌，作為接續含杜薩魯比辛（DOXORUBICIN）在內之輔助化學療法、已使用合併療法（除非有禁忌，至少應包括使用ANTHRACYCLINE抗癌藥）失敗的轉移乳癌、非小細胞肺癌、愛滋病相關卡波西氏肉瘤之第二線療法；與CISPLATIN併用，作為晚期卵巢癌之第一線療法。與GEMCITABINE併用，可使用於曾經使用過ANTHRACYCLINE之局部復發且無法手術切除或轉移性之乳癌病人、與HERCEPTIN併用時，用於治療未接受過化學治療之轉移性且乳癌過度表現HER-2之病人。",
    "劑型": "270注射劑",
    "包裝": "5公撮,16.7公撮,25公撮,50公撮小瓶 100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "PACLITAXEL",
    "限制項目": "02輸　入",
    "申請商名稱": "輝瑞大藥廠股份有限公司",
    "申請商地址": "台北市信義區松仁路100號42、43樓",
    "主製造廠": [
        {
            "製造廠名稱": "HOSPIRA AUSTRALIA PTY LTD.",
            "製造廠廠址": "1-5, 7-23 AND 25-39 LEXIA PLACE, MULGRAVE, VICTORIA 3170, AUSTRALIA",
            "製造廠公司地址": "",
            "製造廠國別": "AUSTRALIA",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "久裕企業股份有限公司",
            "製造廠廠址": "桃園市桃園區大林里興邦路43巷2之1號4樓，3樓B區，1樓A區",
            "製造廠公司地址": "",
            "製造廠國別": "",
            "製程": "二級包裝廠(委託貼標及置入仿單)"
        }
    ],
    "CCC號列": "30049071005 抗癌藥Anti-cancer preparations",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013000100",
            "成分名稱": "PACLITAXEL",
            "含量描述": "",
            "含量": "6.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "Anzatax Injection vial-109-09-18(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02023396&Seq=001&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "Anzatax Injection MOH 20160823-5-109-09-18(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02023396&Seq=009&Type=9"
        },
        {
            "title": "Anzatax LLD MOH 20160823-4-109-03-13.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02023396&Seq=008&Type=9"
        },
        {
            "title": "Anzatax Injection carton-109-09-18(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02023396&Seq=005&Type=8"
        },
        {
            "title": "023396 安莎德斯注射液 Anzatax Conce.100mg Inj. 16.7ml-瓶身外盒-104-10-14(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02023396&Seq=004&Type=8"
        }
    ]
}